Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

被引：106

作者：

Avet-Loiseau, Herve ^{[1
,2
]}

Malard, Florent ^{[2
]}

Campion, Loic ^{[3
]}

Magrangeas, Florence ^{[2
]}

Sebban, Catherine ^{[4
]}

Lioure, Bruno ^{[5
]}

Decaux, Olivier ^{[6
]}

Lamy, Thierry ^{[7
]}

Legros, Laurence ^{[8
]}

Fuzibet, Jean-Gabriel ^{[9
]}

Michallet, Mauricette ^{[10
]}

Corront, Bernadette ^{[11
]}

Lenain, Pascal ^{[12
]}

Hulin, Cyrille ^{[13
]}

Mathiot, Claire ^{[14
]}

Attal, Michel ^{[15
]}

Facon, Thierry ^{[16
]}

Harousseau, Jean-Luc ^{[17
]}

Minvielle, Stephane ^{[2
]}

Moreau, Philippe ^{[18
]}

机构：

[1] Univ Hosp, Hematol Lab, Inst Biol, F-44093 Nantes, France

[2] INSERM, U892, Nantes, France

[3] Ctr Rene Gauducheau, Dept Stat, F-44035 Nantes, France

[4] Ctr Leon Berard, Dept Hematol, F-69373 Lyon, France

[5] Univ Hosp, Dept Hematol, Strasbourg, France

[6] Univ Hosp, Dept Internal Med, Rennes, France

[7] Univ Hosp, Dept Hematol, Rennes, France

[8] Univ Hosp, Dept Hematol, Nice, France

[9] Univ Hosp, Dept Internal Med, Nice, France

[10] Univ Hosp, Dept Hematol, Lyon, France

[11] Univ Hosp, Dept Hematol, Annecy, France

[12] Ctr Francois Baclesse, Dept Hematol, Rouen, France

[13] Univ Hosp, Dept Hematol, Nancy, France

[14] Inst Curie, Hematol Lab, Paris, France

[15] Univ Hosp, Dept Hematol, Toulouse, France

[16] Univ Hosp, Dept Hematol, Lille, France

[17] Ctr Rene Gauducheau, Dept Hematol, F-44035 Nantes, France

[18] Univ Hosp, Dept Hematol, Nantes, France

来源：

BLOOD | 2011年 / 117卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; C-MAF; MAINTENANCE; THALIDOMIDE; EXPRESSION; SURVIVAL; THERAPY; TRIAL; GENE;

D O I：

10.1182/blood-2010-07-295105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retro-spectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma. (Blood. 2011; 117(6): 2009-2011)

引用

页码：2009 / 2011

页数：3

共 50 条

[31] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
Grzasko, Norbert
Hajek, Roman
Hus, Marek
Chocholska, Sylwia
Morawska, Marta
Giannopoulos, Krzysztof
Czarnocki, Krzysztof
Druzd-Sitek, Agnieszka
Pienkowska-Grela, Barbara
Rygier, Jolanta
Usnarska-Zubkiewicz, Lidia
Dytfeld, Dominik
Kubicki, Tadeusz
Jurczyszyn, Artur
Korpysz, Maciej
Dmoszynska, Anna
LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2089 - 2100
[32] Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran, Charlotte
Uttervall, Katarina
Bruchfeld, Johanna Borg
Wallblom, Ann
Alici, Evren
Gahrton, Gosta
Nahi, Hareth
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (06) : 588 - 596
[33] Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
Hebraud, Benjamin
Magrangeas, Florence
Cleynen, Alice
Lauwers-Cances, Valerie
Chretien, Marie-Lorraine
Hulin, Cyrille
Leleu, Xavier
Yon, Edwige
Marit, Gerald
Karlin, Lionel
Roussel, Murielle
Stoppa, Anne-Marie
Belhadj, Karim
Voillat, Laurent
Garderet, Laurent
Macro, Margaret
Caillot, Denis
Mohty, Mohamad
Facon, Thierry
Moreau, Philippe
Attal, Michel
Munshi, Nikhil
Corre, Jill
Minvielle, Stephane
Avet-Loiseau, Herve
BLOOD, 2015, 125 (13) : 2095 - 2100
[34] Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation
Kim, Jin Seok
Kim, Kihyun
Cheong, June-Won
Min, Yoo Hong
Suh, Cheolwon
Kim, Hawk
Jo, Deog Yeon
Ryoo, Hun Mo
Yoon, Sung Soo
Lee, Joe Hoon
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (04) : 463 - 470
[35] An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era
Tan, Daryl
Teoh, Gerrard
Lau, L. C.
Lim, Alvin
Lim, T. H.
Yap, K. C.
Premalatha, P.
Lao, Z. T.
Wee, Nelson
Choo, Christine
Wee, H. C.
Su, S.
Lee, Y. S.
Lee, L. H.
Hwang, William
Goh, Y. T.
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 752 - 756
[36] Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
van Beers, Erik H.
van Vliet, Martin H.
Kuiper, Rowan
de Best, Leonie
Anderson, Kenneth C.
Chari, Ajai
Jagannath, Sundar
Jakubowiak, Andrzej
Kumar, Shaji K.
Levy, Joan B.
Auclair, Daniel
Lonial, Sagar
Reece, Donna
Richardson, Paul
Siegel, David S.
Stewart, A. Keith
Trudel, Suzanne
Vij, Ravi
Zimmerman, Todd M.
Fonseca, Rafael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (09) : 555 - 562
[37] Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma
Pulkki, K
Pelliniemi, TT
Rajamaki, A
Tienhaara, A
Laakso, M
Lahtinen, R
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (02) : 370 - 374
[38] JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
Solimando, A. G.
Brandl, A.
Mattenheimer, K.
Graf, C.
Ritz, M.
Ruckdeschel, A.
Stuehmer, T.
Mokhtari, Z.
Rudelius, M.
Dotterweich, J.
Bittrich, M.
Desantis, V.
Ebert, R.
Trerotoli, P.
Frassanito, M. A.
Rosenwald, A.
Vacca, A.
Einsele, H.
Jakob, F.
Beilhack, A.
LEUKEMIA, 2018, 32 (03) : 736 - 743
[39] Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience
Pasvolsky, Oren
Gaballa, Mahmoud R.
Milton, Denai R.
Masood, Adeel
Sami, Sophiya S.
Tanner, Mark R.
Bashir, Qaiser
Srour, Samer
Saini, Neeraj
Ramdial, Jeremy
Nieto, Yago
Tang, Guilin
Lin, Pei
Lee, Hans C.
Patel, Krina K.
Kebriaei, Partow
Thomas, Sheeba K.
Weber, Donna M.
Orlowski, Robert Z.
Shpall, Elizabeth J.
Champlin, Richard E.
Qazilbash, Muzaffar H.
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (04): : 260.e1 - 260.e6
[40] Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
Garrido, David
Slavutsky, Irma
Riva, Eloisa
CURRENT PROBLEMS IN CANCER, 2023, 47 (01)

← 1 2 3 4 5 →